HIV Vaccines: Time to do what we need to do

HIV Vaccines: Time to do what we need to do

HIV Vaccines: Time to do what we need to do
Inline image

By Jennifer Anyanti MPH

Deputy Managing Director, Society for Family Health

It is interesting how the focus is once again shifting from placing all on treatment to continuing the search for the HIV Vaccine. Everywhere it has been proven that vaccines are more cost effective than treatment, in fact as the adage goes, ‘prevention is better than cure’.

The advantages of a vaccine are innumerable, including the fact that they are reducing the need for expensive social and behavioural change messages which, while necessary, tend to be quite expensive.

These are funds that could be shifted into purchasing more vaccines, and allow governments and non-governmental actors to address other areas of programing, including strengthening supply chains which will favour other areas of health.

In addition, the vaccine can target children, and infants that may become infected due to MTCT, which in countries like Nigeria, is still proving to be a tough nut to crack with less than 50% of those who need treatment being on treatment.

Also, in view of the challenges with funding health care in Nigeria and reaching the numbers in the Abuja declaration of 15% for health (http://www.who.int/healthsystems/publications/abuja_declaration/en/), Nigeria was still at less than 5%, except in one state (https://www.dailytrust.com.ng/2018-budget-bauchi-allocates-18-8-to-education-15-23-to-health-sectors.html) and as a result more funds can be used to address the plethora of diseases yet to be addressed in Nigeria.

Despite the advantages inherent in having a vaccine, some key issues need to be addressed. As stated by Gary J. Nabel of the Vaccine Research CenterNIH, in Bethesda, Maryland, a number of areas must be taken into consideration before scientific research will culminate in a definitive AIDS vaccine.

These include the need for greater translation between animal models and human trials and the fact that new, more effective, and more easily produced vectors must be identified.

It is also obvious that the understanding of the immune response to potential vaccine candidates is still yet to be clear.

In addition, in Africa which is still the worse continent affected by the epidemic, insufficient work is being done on research into a vaccine, apart for trials, which are more often than not externally funded.

The need to collaborate strongly with African institutes of research and community advocates cannot be over emphasized.

Also, the issues that also affect vaccination in general such as supply chains, strategic behavioral communication for change and training of health workers will also require consideration and planning.

The hope is that an effective vaccine for HIV could be completed in the next few years (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401528/). Well, millions of those affected or at risk of being affected by HIV are waiting with bated breath.

 

Understanding diversity in vaginal microbiomes: A gateway to an effective HIV vaccine

Understanding diversity in vaginal microbiomes: A gateway to an effective HIV vaccine

Understanding diversity in vaginal microbiomes: A gateway to an effective HIV vaccine
Inline imageInline image

By Constancia Mavodza, Sexual and Reproductive Health and Rights (SRHR) Research Analyst, Global Health Corps Fellow at the Centre for Health and Gender Equity (CHANGE) and Kate Segal, SRHR Policy Analyst, Global Health Corps Fellow at CHANGE.

An exciting emerging research canon that identifies links between vaginal bacteria and HIV underscores the need to prioritize women’s participation in HIV vaccine research. Because HIV passes through the vaginal lining and the female genital tract has a larger surface area than male genitalia, women face greater risk of HIV transmission from heterosexual vaginal intercourse.

But getting women in the door for clinical trials is difficult. Building trust with researchers and providers as well as structural disadvantages and societal barriers inhibit their participation in particular ways. For effective HIV prevention methods and an eventual vaccine, it is particularly important to recruit a diverse group of women – including pregnant women – for HIV vaccine clinical trials. Women’s inclusion in HIV vaccine research recognizes the unique biological factors that increase their HIV risk and ensures that women will receive evidence-informed care.

Adolescent girls and young women aged 15-24 comprise 60 percent of youth living with HIV globally, and in sub-Saharan Africa, adolescent girls and young women account for 74 percent of new HIV infections among youth. Discussions around risk reduction for this group have largely centered on behavioral indicators of adolescent girls and young women, such as having intergenerational sex. While certain behaviors can put girls and women at greater risk of HIV, focusing solely on social and behavioral drivers can veer into moral policing of sexual proclivities that is acutely gendered, particularly because some women cannot negotiate condom use and/or monogamy.

Physiological composition and biological mechanisms in HIV infection are different for men and women. For instance, there are sex-specific differences in HIV viral loads and CD4 counts, as well as in adverse responses to antiretroviral therapy. For adolescent girls, inflammation of the genitalia and greater presence of mucus in the immature cervix increase their vulnerability.

Another biological factor that makes women distinctively susceptible to HIV acquisition is the vaginal microbiome. The vaginal microbiome, or bacterial communities in the vagina, has been found to both increase and decrease HIV risk, depending on a woman’s bacterial makeup.

A recent study of six Eastern and Southern African countries identified seven types of vaginal bacteria that, when highly concentrated, are associated with increased vulnerability to HIV acquisition. It also found that women who acquired HIV had more diversity of bacteria in the microbiome. These findings were consistent for pregnant and post-partum women, female sex workers, and women in serodiscordant relationships (where only one partner is living with HIV).

The vaginal microbiome has also been found to impact the efficacy of antiretroviral drugs for HIV prevention. Results from a clinical trial of one microbicide found that for women whose microbiomes have a high prevalence of one particular bacteria, Lactobacillus, the medicine had significantly higher efficacy than for women in whom this bacteria is not dominant. Relatedly, women with a higher presence of Lactobacillus bacteria were associated with a lower risk of HIV infection.

What’s more, this study found regional differences in women’s vaginal bacteria concentrations: 90 percent of white women in developed countries had Lactobacillus-dominant microbiomes, compared with the majority of women from South Africa, who exhibited low Lactobacillus presence. That geography can be a determinant of your HIV risk indicates that behavioral and social factors can only explain so much, and including a diverse group of women — with diverse microbiomes — in clinical research is key to developing an effective vaccine that is suited to all populations.

Biological changes that happen during pregnancy may also heighten women’s vulnerability to HIV. Two studies found that for African HIV-negative women that are pregnant and in sexual relationships with men living with HIV, the risk of HIV transmission per sex act increased throughout pregnancy, and was highest during the six-month post-partum period. Relative to risk of HIV acquisition when not pregnant, which is approximately five percent, the studies found that the risk of infection was 2.91 times higher during the first trimester, 2.97 times higher during the second two trimesters, and 4.18 times higher post-partum. A biological mechanism called vaginal thinning, which takes place throughout pregnancy, could be the reason pregnant and post-partum women are more susceptible to HIV.

We have an opportunity to acknowledge the diversity of women’s bodies in HIV vaccine research and come up with solutions that are reflective of this complexity. Evidence that the vaginal microbiome and vaginal thinning affect women’s chances of acquiring HIV and response to HIV prevention drugs rightfully disrupts harmful narratives that concentrate too heavily on women’s sexual behavior.

Without accounting for women and the incredible variation in vaginal microbiomes, an effective HIV vaccine will remain out of reach. HIV clinical trials must include women to understand the factors that put particular groups at greater risk of HIV.

As 2018 Civil Society Accountability Forum in Nigeria holds in November, can government be accountable to its promises? – Dr. Folayan

By Morenike Oluwatoyin Folayan

The 2018 edition of the Civil Society Accountability Forum is scheduled to hold on the 13th to 15th of November, 2018 in Abuja, Nigeria. The theme for this year’s conference is “Domestic Resource Mobilisation: Public and Private Sector Investment”.The government – national, state and local – is expected to discuss domestic financing of the HIV response in Nigeria at the forum. This comes up closing on the heels of the commitment made by the Minister of Health, Prof Isaac Adewole at the PEPFAR 2018 COP meeting in Johannesburg, South Africa where he committed to performing a miracle by getting the Nigeria government to take substantial responsibility of the HIV treatment programme by funding procurement of commodities for the response.

He made this statement on the 22nd of February 2018 at the closing of the five days PEPFAR 2018 COP planning meeting.Adewole noted that like South Africa, Nigeria should be leading its National Response and donors should only be complimenting the response. Sadly, this is the reverse.

Nigeria currently funds less than 20% of the National HIV response. The country also has no strategic plans on how it plans to transit the currently heavily PEPFAR and Global Fund subsidized response.The country also has no annual plan that monitors how stakeholders strategically contribute to meeting set targets for the elimination of new HIV infections in the country.

Nigeria has one of the highest number of new HIV infection in Sub-Saharan Africa – in 2016, over 200,000 persons were infected with HIV (https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/nigeria).In an effort to reposition the country, the Ministry of Health (NASCP) conveyed a meeting in Lagos in March 2018, to begin preliminary discussions on national funding of the HIV treatment in Nigeria. This is essential as there are current efforts to phase out the use of Efavirenz and replace this with Dolutagravir.

PEPFAR is already going ahead with the plan to switch therapy. Dolutagravir is more user-friendly, with less side effects and cost effective. The Civil Society under the leadership of Treatment Action Movement in collaboration with Afrocab, had been very active with pushing the country to switch therapy. This was one of the agenda for discussion at the 2016 Civil Society Accountability Forum.

The NASCP meeting not only focused on how to re-establish the national HIV treatment programme, but it also developed a roadmap for the prevention of mother to child transmission of HIV in Nigeria. The roadmap was to have been presented to the Minister by the end of March 2018.
Unlike the Federal Ministry of Health, the National Agency for the Control of AIDS under the leadership of Dr Sani Aliyu, is focused not just on preventing mother to child transmission of HIV, but eliminating it in line with its 2017-2021 HIV and AIDS strategic plan. Nigeria contributes significantly to the global HIV epidemic having the highest number of babies born with HIV in the world. This is partly because only 30% of mothers living with HIV actually have access to HIV treatment programmes that can reduce the risk of mother to child transmission of HIV infection.

With the Minister committing to performing a miracle with the national HIV treatment programme before the coming in of a new government in 2019; and the National Agency for the Control of AIDS focusing its resources to eliminate mother to child transmission of HIV in Nigeria, it is critically important to listen to how the government has fared to date knowing 2020 is a miracle year for all – when AIDS should cease to be a global epidemic.Can Nigeria keep its global commitment to the 2020 goal? We look forward to answers at the 2018 Civil Society Accountability Forum.

Folayan is of New HIV Vaccine and Microbicide Advocacy Society

Just Speak out against sexual harassment! – Elizabeth Oladipo

Just Speak out against sexual harassment! – Elizabeth Oladipo

Any form of abuse meted out to adolescent girls may inflict in them negative consequences. It is therefore important not to prevent the abuser  from facing the consequences of the law. Adolescents need not keep silent about abuses they face. It is your responsibility to voice out. Abuse is not anyone’s fault. People who abuse have a way of instilling fear and shutting the abused up.  Forced sex is RAPE and it is a crime. There are also other forms of sexual harassment such as touching or grabbing intimate body parts for sexual gratification. Sexual assault is not just a crime of sex; it is also a crime of power and control, where sexual activity is used to dominate and hurt the victim. For adolescents and young adults, it can occur during a date. Prevention requires being proactive at social gathering to avoid molestation.

Join the #MeToo Campaign. Lets break the silence on sexual harassment

Enhancing the effectiveness of antiretroviral for HIV Prevention: Lessons from CROI – Alaka Oluwatosin

Enhancing the effectiveness of antiretroviral for HIV Prevention: Lessons from CROI – Alaka Oluwatosin

In the words of Professor Wafaa M. El-Sadir of the Columbia University, USA and the lead for the ICAP project, HIV management has passed through Trials, Travails and Triumphs with HIV epidemic evolving from an untreatable deadly disease to a chronic manageable condition.

As she discussed HIV prevention at the 25th anniversary of CROI held in Boston, USA from the 4th to the 7th of March 2018, she noted that despite the seeming success, new HIV infection continues and it is highly unlikely that the world would be able to reach the goal of less than half a million new infections per year by 2020. “This should compel us to think about how we can do better in terms of preventing new HIV infections,” she said.

Access to antiretroviral treatment should help expedite HIV prevention. In this case, treatment is used as prevention (TasP). Once antiretroviral therapy is adhered to, viral suppression occurs, and individuals living with the virus cannot transmit the virus. Similarly, adherence is required for antiretroviral used as pre-exposure prophylaxis (PrEP) to work.

Adherence to therapy can only be enhanced when supported with other intervention measures such as harm-reduction strategies for people who inject drugs, mental health service support for people who require this, access to regular HIV testing services, and empowerment programmes for adolescents and female sex workers.

Without these support, a population level effectiveness of treatment as prevention and pre-exposure prophylaxis would be limited in high HIV prevalence countries says Prof. Roel Coutinho from the University Medical centre Utrecht, Netherlands.

Meanwhile, mental health management of persons taking antiretroviral therapy for HIV infection management is also critical.

To control the epidemic, mental health care needs to be instituted as part of comprehensive HIV management, noted Dr. Robert H. Remien, a Professor of Clinical Psychology at the Columbia University, USA.

Poor mental health itself increases the risk of acquiring HIV infections for persons who are HIV negative as it negatively affects adherence to use of antiretroviral therapy as PrEP. It also doubles the risk of mortality for persons taking antiretroviral therapy for HIV infection management.

HIV prevention and treatment is best achieved through combination and integrated service delivery. All HIV management interventions proven effective need to be integrated into a combination of health-strengthening strategies to achieve effectiveness noted El-Sadir.

She also discussed the need for precision intervention by learning about WHERE to focus (geographic area), WHO to focus on (specific population), HOW to focus (models of prevention) and also WHAT type of tools we would use for the identified population(s).

The ability to learn how to conduct such precision interventions in Africa is limited by the capacity of local researchers to effectively oversee all aspects of the grant management cycle. Researchers in Africa have therefore had to depend on foreign partners for research administration, noted Dr. Elizabeth Bukusi of the Kenya Medical Research Institute, Nairobi, Kenya, during one of the breakfast sessions held at the conference.

“We don’t have strong management systems. Although we talk about issues of corruption, the systems are not robust enough to be able to manage research funds as we would want them; hence funds are being managed largely from the West,” Bukusi said.

“It is imperative to strengthen research administration through infrastructural, organizational, and human resource development to match the dynamic research environment and funding requirements.

“If we don’t address that capacity gap, it makes it difficult to grow the research to fit into our specific needs.”

“It was also identified that another issue we face is in infrastructural development. Facilities, resources and related services that are used by the scientific community are critical to conduct top-level research, without which, we will not be able to do the quality science that we desire,” she said.

Lots of changes have happened with the HIV prevention and treatment field over the last 35 years of the HIV epidemic. There have been indeed trials, travails and successes. The gain we have jointly made will require the sustained engagement and unique inputs from various communities, inclusive of small informal groups at the grass-roots and those of global coalitions. The struggle continues.

By Alaka Oluwatosin Bamidele

 

Oluwatosin, of New HIV Vaccine and Microbicide Advocacy Society (NHVMAS), writes in from Lagos.

Make the home a sexuality education school – Amos Fortune

Make the home a sexuality education school – Amos Fortune

Parents are the greatest assets for children. We are subject to the laws and mandates of our parents. I probably speak as such because I have very tough parents and I know what it is to live by their rules. and laws. I know what it is to grown up with different parents and I do have an insight into why adolescents may be considered rebellious. My father was extremely tough. He was had little accommodations for nonsense from we his children. He was very strict. He never wanted me to associate freely with anything outsde the christian world. He therefore restricted my knowledge and activities. Things were a lot easier because of my understanding mum. Sadly, this is the stage of life where adolescents are curious and want to explore. They will explore in these kind of gagged atmosphere but sadly, the exploration will be without parental guidance. Strict parents loose their children at this time as adolescents seek for knowledge from alternative sources. Parents should include early sex education for their children as part of the education they inculcate in the homes. Sex education should not be given in harsh manner. Just the way religion is taught to kids in the home, teach sex and sexuality to kids in the home. Home sexual education training is essential for adolescents as part of the love, care, correction and attention they need. Times are changing and parents also need to change with the changing times

Amos Fortune